Acadia Pharmaceuticals ? maker of the controversial psychosis drug Nuplazid ? is stopping a late-stage trial testing of the drug in patients with dementia, in response to an early signal suggestive of the drug?s efficacy.
The San Diego-based company has been doing its best to expand the market for the drug, which was originally cleared for Parkinson?s disease psychosis. The sedative, which generated sales of about $146 million in the first half of this year, gained notoriety after a series of reports suggested its maker had misrepresented the dangers of using the drug and employed questionable tactics to market it, prompting an FDA review that later reaffirmed the drug?s safety profile.
Like the contentious design Acadia emplo